Clinical promise of tumour immunology

Lancet

Volumn 349, Issue SUPPL.2, 1997, Pages

  Scott, Andrew M ^a   Cebon, Jonathan ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CANCER VACCINE; IMMUNOLOGICAL ADJUVANT; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ANTIGEN RECOGNITION; CANCER; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; HUMAN; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0031009249     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(97)90016-7     Document Type: Article

References (28)

1. Coley WB. The treatment of malignant tumurs by repeated inoculations of erysipelas with a report of 10 original cases. Am J Med Sci 1893; 105: 487.
2. Old LJ. Immunotherapy for cancer. Sci Am 1996; Sept:136-43.
3. Papadopoulos EB, Ladauyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185-91.
4. Smyth M, Trapani J. Granzymes: exogenous proteinases that induce target cell apoptosis Immunol Today 1995; 16: 202-06.
5. Boon T, Cerottini J-C, Van den Eynde B, Van den Bruggen P. Tumour antigens recognised by T-lymphocytes. Annu Rev Immunol 1994; 12: 337-65.
6. Sahin U, Tureci O, Schmitt H, et al Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995; 92: 11810-13.
7. Chen Y-T, Scanlan M J, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94: 1914-18.
8. Jager E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for irnrmmoselection of antigen-loss variants in vivo. Int J Cancer 1996; 66: 470-76.
9. Kawakami Y, Robbins PF, Wang RF, Rosenberg SA. Identification of tumor-regression antigens in melanoma. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Important advances in oncology. Philadelphia: Lippincott-Raven, 1996: 3-21.
10. Houghton AN, Chapman PB, Bajorin DR. Antibodies in cancer therapy: clinical applications-melanoma. In: Devita VT Jr, Hellman S, Rosenberg SA, eds. Biologic therapy of cancer. Philadelphia: Lippincott, 1991: 533-49.
11. Welt S, Scott AM, Divgi CR, et al. Phase I/II study of iodine-125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1996; 14: 1573-62.
12. Goldenberg DM, ed. Cancer therapy with radiolabelled monoclonal antibodies. Boca Raton: CRC Press, 1995.
13. Hird V, Maraveyas A, Snook D, et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 1993; 68: 403-06.
14. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanised anti-pi85 HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737-44.
15. Welt S, Divgi CR, Scott AM, et al. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell surface protein of reactive tumor stromal fibroblasts. J Clin Oncol 1994; 12: 1193-03.
16. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granuiocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-43.
17. Jager E, Ringhoffer M, Dienes HP, et al. Granuiocyte-macrophage colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 1996; 67: 54-62.
18. Restifo NP. The new vaccines: building viruses that elicit antitumor immunity. Curr Opin Immunol 1996; 8: 658-63.
19. Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996; 183: 87-97.
20. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2: 52-58.
21. Marchand M, Weynants P, Rankin E, et al. Tumour regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995; 63: 883-85.
22. Winter G, Milstein C. Man-made antibodies. Nature 1991; 349: 293-99.
23. Jakobovits A, Green LL, Hardy MC, et al. Production of antigen-specific human antibodies from mice engineered with human heavy and light chain YACs. Ann N Y Acad Sci 1995; 764: 525-35.
24. Renner C, Jung W, Sahin U, et al. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 1994; 264: 833-35.
25. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996; 14: 1974-81.
26. Livingston PO, Wong GYC, Adhuri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994; 12: 1036-44.
27. Riethmuller G, Schneider-Gadicke E, Schlimok G, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 1994; 343: 1177-83.
28. Caron PC, Jurcic JG, Scott AM, et al. A phase IB trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood 1994; 83: 1760-68.